Randy Lieber - Cellcyte Genetics Insider

Cellcyte Genetics -- USA Stock  

USD 0.0001  0.00  0.00%

Principal Accounting Officer, Director

Mr. Randy A. Lieber is Principal Accounting Officer and Director of CellCyte Genetics Corporationrationration. He is a senior financial professional with more than 29 years of experience working with both public and private companies. He is also the Chief Financial Officer of Blink Interactive, Inc., a user experience, research and design firm based in Seattle, WA. Mr. Lieber started his professional career at Coopers LybrandPricewaterhouseCoopers where he spent 14 years working with a wide range of companies including software, semiconductor, biotechnology and Internet companies. While at PwC, he was involved in more than 10 initial and followon public offerings, financial reporting to the Securities and Exchange Commission, and provided buyside consulting and due diligence on mergers and acquisitions. Subsequent to his tenure at PwC, Mr. Lieber was the Director of Finance at a 500 million international public company, Chief Financial Officer of an internet startup company, and more recently, as the Chief Financial Officer of Ascentium Corporationrationration, a technology and marketing consulting firm. He joined Ascentium shortly after it was founded in 2001 and was instrumental in helping it to grow to annual revenues of 75 Million with offices in seven cities, including London. He was responsible for all finance, accounting, human resources, and facilities
Age: 55  Director Since 2008  CPA    
425-519-3755  http://www.cellcyte.com
Lieber has BS degree in accounting from Central Washington University and became a CPA in Alaska in 1987 and in California in 1996. He is on the Board of Directors of the Greater Seattle USBC Youth Bowling Association and the Greater Seattle USBC Association.

Management Efficiency

The company has return on total asset (ROA) of (415.29) % which means that it has lost $415.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (22.9) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives

DIRECTOR Since

Marco CostaBanco do Brasil S A
N/A
Marco CastroBanco do Brasil S A
2015
Miguel MattosBanco do Brasil S A
N/A
Beny ParnesBanco do Brasil S A
2015
Alexandre SouzaBanco do Brasil S A
N/A
Bernardo RotheBanco do Brasil S A
2015
Daniel SigelmannBanco do Brasil S A
N/A
Luiz SantosBanco do Brasil S A
2015
Tarcisio GodoyBanco do Brasil S A
N/A
Adriana CarvalhoBanco do Brasil S A
2015
Edson CardozoBanco do Brasil S A
N/A
Juliana OliveiraBanco do Brasil S A
2015
Jose MinchilloBanco do Brasil S A
2016
Fabiano FontesBanco do Brasil S A
N/A
Cicero PrzendsiukBanco do Brasil S A
N/A
Francisco GaetaniBanco do Brasil S A
2010
Jose BergoBanco do Brasil S A
N/A
Marco MendoncaBanco do Brasil S A
N/A
Reinaldo YokoyamaBanco do Brasil S A
N/A
Gustavo FosseBanco do Brasil S A
N/A
Bernardo MacedoBanco do Brasil S A
N/A

Entity Summary

CellCyte Genetics Corporationration, a development stage biotechnology company, engages in the research and development of medical devices for cell expansion and maintenance in the United States. Cellcyte Genetics [CCYG] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Did you try this?

Run Idea Optimizer Now
   

Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Hide  View All  NextLaunch Idea Optimizer
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Cellcyte Genetics to your portfolio

Other Leaders

Cellcyte Genetics Management Team
John Fluke, Chairman
Randy Lieber, Director, CPA
Douglas Cerretti, President, Ph.D

Stock Performance

Cellcyte Genetics Performance Indicators